Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 30, 2020
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, Dane Cheasley, Cecile LePage, et al.
Gynecologic Oncology|June 7, 2025
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysisZhuxuan Fu, Lauren Borho, Sarah E Taylor, et al.
The Journal of Pathology|December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomasKarolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesNicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Research Square|November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaDale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Pageof 10